Generative artificial intelligence conversational agents in mental health care: clinical evidence, psychosocial risks and governance. A narrative review
SAP Social AI · 2026
DOI: 10.62486/sai2026109 ↗Kurz gefasst
Fachartikel in der Zeitschrift SAP Social AI, 2026. Verfasst von Maikro Osvaldo Chávez Moya und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction: conversational agents based on generative artificial intelligence (AI) are increasingly used for emotional support, largely outside clinical frameworks. Objective: to synthesise the available evidence on the clinical efficacy, the clinical and psychosocial risks, and the governance of generative AI conversational agents in mental health, and to identify implications for clinical practice and health policy. Methods: narrative review based on a non-systematic search of randomised trials, systematic reviews, observational and experimental studies, technical evaluations and regulatory documents, with a qualitative synthesis organised in four areas. Development: in a national survey, 13.1% of US youths aged 12 to 21 reported using generative AI for mental health advice. A meta-analysis of AI-based conversational agents showed reductions in depressive symptoms and distress, and the first randomised trial of a purpose-built generative agent reported greater symptom reduction than a waitlist over four weeks, whereas a pilot trial in Argentina found no significant between-group differences. Documented risks include stigma and inappropriate responses, inconsistent handling of intermediate-risk suicide-related queries, sycophancy, reinforcement of delusional thinking and emotional dependence. Regulation is fragmented: at its November 2025 advisory meeting the US Food and Drug Administration noted that no authorised AI-enabled device used generative AI for mental health conditions, US states have adopted divergent laws, and the European Union AI Act imposes transparency obligations. Conclusions: evidence of benefit comes mainly from purpose-built agents tested in short trials, whereas real-world use relies on general-purpose and companion chatbots. These tools should be considered a complement to, not a substitute for, clinical care, with risk-based regulation, independent auditing, age-appropriate safeguards and trials in Spanish- and Portuguese-speaking populations.
Zitieren
APA
Moya, M. O. C., Cabrera, L. H., Ramírez, L. M., González, M. A. G., Pazos, A. A., Feitó, L. B. F., & Pernas, G. G. (2026). Generative artificial intelligence conversational agents in mental health care: clinical evidence, psychosocial risks and governance. A narrative review. SAP Social AI. https://doi.org/10.62486/sai2026109
Vancouver
Moya MOC, Cabrera LH, Ramírez LM, González MAG, Pazos AA, Feitó LBF, et al. Generative artificial intelligence conversational agents in mental health care: clinical evidence, psychosocial risks and governance. A narrative review. SAP Social AI. 2026. doi:10.62486/sai2026109
BibTeX
@article{Moya2026,
author = {Moya, Maikro Osvaldo Chávez and Cabrera, Leodanis Hernández and Ramírez, Lauren Martínez and González, Mariam Alejandra González and Pazos, Andy Alonso and Feitó, Laura Beatriz Fernández and Pernas, Gabriela González},
title = {Generative artificial intelligence conversational agents in mental health care: clinical evidence, psychosocial risks and governance. A narrative review},
journal = {SAP Social AI},
year = {2026},
doi = {10.62486/sai2026109}
}
EUVIMED